Sanofi Feeling Positive On Cialis Switch Progression As Q2 Sales Rise
Executive Summary
As Sanofi reports Consumer Healthcare second-quarter sales up by 9%, the company is hopeful it can progress its plan to switch erectile dysfunction drug Cialis in the US following a constructive meeting with the FDA.
You may also be interested in...
Sanofi Sees Tough Economic Environment Start To Temper Demand
Sanofi Consumer Healthcare is starting to feel the effects of the tough economic environment, with signs of "growth moderation" in recent months. While the firm's global Q3 sales advanced by almost 2%, turnover in the US was hit by a "broad market slowdown."
Euro Q3 Consumer Health Earnings Preview: Helm Changes, Investor Questions, Results Debut
Major Europe-based consumer health players Reckitt, Bayer, Sanofi and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2022 results over the coming weeks.
German Government Wants Sildenafil, Tadalafil OTC
Germany's Ministry of Health surprised all those present at a recent BAH meeting by announcing it would like to see erectile dysfunction drugs like sildenafil and tadalafil available OTC. Such a move, however, would put the government at odds with drug regulator BfArM's Expert Committee for Prescription, which recently rejected an application for the Rx-to-OTC switch of sildenafil.